NYSE$PRGO
Perrigo Company · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Perrigo's financial performance in Q2 2022 showed net sales increase, driven by strong demand for consumer self-care products and strategic acquisitions, despite facing inflationary headwinds and adverse currency translation.
Perrigo reported a strong second quarter with a 14.3% increase in net sales to $1.1 billion, driven by consumer self-care products and the acquisition of HRA Pharma. Despite inflationary pressures and currency translation impacts, the company saw improvements in adjusted gross margin and maintained its full-year outlook.
- Net sales increased by 14.3% to $1.1 billion, with organic net sales up 17.2%.
- Reported EPS was a loss of ($0.48), while adjusted EPS was $0.43 per diluted share.
- The company submitted Opill® application to the FDA and launched NasonexTM 24HR in the U.S.
- Fiscal year 2022 organic net sales growth outlook increased to 9.0%-10.0%, with adjusted EPS range updated to $2.25-$2.35.
Headline financials
Revenue & EPS history
Perrigo · Revenue · Quarterly
$1.12B
Revenue by segment
Perrigo · $1.12B total across 2 segments · Q2 2022
- Consumer Self-Care Americas$728M+17.0%64.9%
- Consumer Self-Care International$394M+9.8%35.1%
Forward guidance
Perrigo is increasing its fiscal 2022 organic net sales growth range outlook to 9.0%-10.0%, from 8.0%-9.0%, versus the prior year, due to continued strong global consumer demand. The Company is reaffirming its fiscal 2022 total net sales growth range outlook of 8.5%-9.5%, as the organic net sales growth outlook increase is expected to be offset by the worsening impact of currency translation. The Company expects to achieve a fiscal 2022 constant currency adjusted EPS range outlook of $2.40-$2.50 per diluted share and is updating its fiscal 2022 adjusted EPS range outlook to $2.25-$2.35 from $2.30-$2.40, due entirely to the worsening impact of currency translation.
Tailwinds
- Increased fiscal 2022 organic net sales growth range outlook to 9.0%-10.0% from 8.0%-9.0% versus the prior year.
- Reaffirms fiscal 2022 total net sales growth range outlook of 8.5%-9.5%.
- Expects to achieve constant currency adjusted EPS range outlook of $2.40-$2.50 per diluted share.
- Updates adjusted EPS range outlook to $2.25-$2.35 from $2.30-$2.40.
- Continues to expect an adjusted effective tax rate of approximately 23%.
Headwinds
- Worsening impact of currency translation is expected to offset the organic net sales growth.
- Adjusted EPS range outlook updated to $2.25-$2.35 from $2.30-$2.40 due to currency translation.
- Cannot reconcile its organic net sales growth to reported net sales.
- Cannot reconcile its expected adjusted diluted EPS or constant currency adjusted EPS to diluted EPS under 'Fiscal 2022 Outlook'.
- Uncertainty regarding the timing of, and the Company’s ability to obtain and maintain, certain regulatory approvals, including the sale of daily over-the-counter oral contraceptives.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.5%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-3.4%
Avg return
30 days after
48%
30 / 63 earnings
Positive
+20.2%
Q4 2024
Best reaction
-25.2%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | -5.0% | -7.0% | |
| Q4 2025 | -1.5% | -21.0% | -33.9% | |
| Q3 2025 | -25.2% | -29.4% | -33.4% | |
| Q1 2025 | +7.2% | +9.4% | +6.0% | |
| Q4 2024 | +20.2% | +22.1% | +16.3% | |
| Q3 2024 | +6.2% | +5.4% | +10.7% | |
| Q2 2024 | +1.8% | -1.5% | +3.3% | |
| Q1 2024 | -6.9% | -8.1% | -19.2% | |
| Q4 2023 | -17.9% | -18.2% | +0.1% | |
| Q3 2023 | +2.0% | -0.2% | +7.3% | |
| Q2 2023 | +5.8% | +7.3% | -8.4% | |
| Q1 2023 | +1.3% | -2.2% | -6.5% | |
| Q4 2022 | +3.9% | +6.9% | -3.2% | |
| Q3 2022 | -18.3% | -14.9% | -18.2% | |
| Q2 2022 | -1.9% | -1.7% | -9.3% | |
| Q1 2022 | +9.1% | +15.6% | +19.7% | |
| Q4 2021 | +6.4% | +4.8% | +8.2% | |
| Q3 2021 | -8.7% | -9.8% | -23.0% | |
| Q2 2021 | -16.0% | -16.6% | -11.1% | |
| Q1 2021 | +6.1% | +6.4% | +13.3% | |
| Q4 2020 | +4.3% | +1.7% | +0.3% | |
| Q3 2020 | -0.3% | +1.5% | +9.9% | |
| Q2 2020 | -8.5% | -6.1% | -7.7% | |
| Q1 2020 | -3.0% | -4.4% | +0.8% | |
| Q4 2019 | -16.4% | -12.1% | -24.0% | |
| Q3 2019 | -8.1% | -9.3% | -3.4% | |
| Q2 2019 | -7.1% | -5.4% | -1.1% | |
| Q1 2019 | +7.5% | +1.7% | -10.1% | |
| Q4 2018 | +0.8% | +4.0% | -0.3% | |
| Q3 2018 | -14.7% | -13.0% | -20.2% | |
| Q2 2018 | -10.7% | -11.3% | -3.3% | |
| Q1 2018 | -4.9% | +0.4% | -5.2% | |
| Q4 2017 | +1.9% | -6.0% | -5.6% | |
| Q3 2017 | +8.0% | +5.9% | +5.4% | |
| Q2 2017 | +18.3% | +17.2% | +24.7% | |
| Q1 2017 | +4.1% | +5.0% | +8.5% | |
| Q3 2016 | +6.9% | +6.7% | -1.2% | |
| Q2 2016 | -9.8% | -7.2% | -6.7% | |
| Q1 2016 | -4.7% | — | — | |
| Q4 2015 | -10.9% | — | — | |
| Q3 2015 | -1.3% | — | — | |
| Q2 2015 | +1.7% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | +6.7% | — | — | |
| Q3 2014 | -11.3% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | +10.7% | — | — | |
| Q4 2013 | -5.1% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | +5.2% | — | — | |
| Q1 2013 | -8.8% | — | — | |
| Q4 2012 | -8.3% | — | — | |
| Q3 2012 | -4.5% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q3 2011 | -7.6% | — | — | |
| Q2 2011 | +2.7% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q4 2010 | +0.6% | — | — | |
| Q3 2010 | -0.1% | — | — | |
| Q2 2010 | -2.9% | — | — | |
| Q1 2010 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro